IceCure Medical Investor Relations Material

IceCure Medical Ltd. is a commercial-stage medical device company that focuses on the development and marketing of cryoablation systems. Utilizing liquid nitrogen-based technology, the company offers minimally invasive treatments for both benign and malignant tumors, primarily targeting applications in women's health and interventional oncology. IceCure Medical's flagship product, the ProSense Cryoablation System, destroys tumors by freezing them, providing an alternative to traditional surgical tumor removal. IceCure Medical Ltd. is headquartered in Caesarea, Israel, and its shares are listed on the NASDAQ.